The PIK3R3 antibody targets the phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), a regulatory component of the class IA phosphatidylinositol 3-kinase (PI3K) family. PI3Ks are lipid kinases critical for intracellular signaling, regulating processes like cell growth, survival, metabolism, and motility. PIK3R3. also known as p55γ, binds to the p110γ catalytic subunit to form the PI3Kγ complex, which is predominantly expressed in immune cells and plays a role in inflammatory responses and immune regulation. Unlike other regulatory subunits (e.g., PIK3R1/R2), PIK3R3 has unique structural features, including a shorter N-terminal domain, which may influence its functional specificity.
Antibodies against PIK3R3 are widely used in research to study its expression, localization, and interaction partners in normal and diseased tissues. They are essential tools for techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. Dysregulation of PIK3R3 has been implicated in cancer, inflammation, and metabolic disorders, with studies linking its overexpression to tumor progression, drug resistance, and altered PI3K/AKT/mTOR signaling. Commercially available PIK3R3 antibodies are typically developed in rabbits or mice, validated for specificity through knockdown/knockout controls. Researchers rely on these reagents to explore PIK3R3's role as a potential therapeutic target or biomarker, though challenges remain in distinguishing isoforms and ensuring cross-reactivity across species.